Paclitaxel

製品コードS1150 別名:NSC 125973

Paclitaxel化学構造

分子量(MW):853.91

Paclitaxelは一種microtubulポリマー(polymer)安定剤で、人間内皮細胞の中にIC50値が0.1 pMです。

サイズ 価格(税別) 在庫  
JPY 15106.00 あり
JPY 11620.00 あり
JPY 44820.00 あり

カスタマーフィードバック(4)

  • Characterization of nuclear damage by PARP as DNA damage repair marker. CLSM images of dual drug conjugated nanoparticle treatments to HeLa cells for 24 h at their respective IC50 drug dosages compared to nontreated control. Cells were stained with PARP-Alexafluor 488 antibody (green).

    ACS Appl Mater Interfaces, 2015, 7(14): 7584-98. Paclitaxel purchased from Selleck.

    Microscope image (406) magnification of U937 cells after exposure to SM-TNs. a) Untreated U937 cells. b) U937 cells treated with 200 nM, and 35 nM ODS empty shells. c) U937 cells treated with microcrystalline (free) Taxol prepared by sonicating Taxol in 20%H3PO4/0.8% SDS solution. d) U937 cells treated with 200 nM SM-TN. A SM-TN is seen in the middle of the picture. e) U937 cells treated with 35 nM SMTN.The nanowires are too small to see at this magnification, but their effect on the cells is clearly visible. Scale bar = 10 mm.

    RSC Adv 2011 1, 884-892. Paclitaxel purchased from Selleck.

  • Inhibitory effect of lenvatinib and paclitaxel on the proliferation of ATC cells. Cells were treated with the indicated concentrations of lenvatinib (A) and paclitaxel (B) for 48 h, followed by MTT assay to evaluate cell proliferation. IC50 values of these two drugs for each cell line were calculated using the Reed-Muench method

    Am J Cancer Res, 2017, 7(4):903-912. Paclitaxel purchased from Selleck.

    Western blot analysis of pPRAS40 (T246), pS6 (S240/S244), and pS6 (S235/S236) proteins in (A) HeyA8 cells and (B) SKOV3 cells treated with 0.37 μM or 10 μM paclitaxel in three-dimensional cell culture for 24 hours.

    PLoS One, 2016, 11(5):e0155052. . Paclitaxel purchased from Selleck.

製品安全説明書

Microtubule Associated阻害剤の選択性比較

生物活性

製品説明 Paclitaxelは一種microtubulポリマー(polymer)安定剤で、人間内皮細胞の中にIC50値が0.1 pMです。
ターゲット
Microtubule (human endothelial cells) [1]
0.1 pM
体外試験

Paclitaxel inhibits non-endothelial type human cells at 104 - to 105 -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. [1] In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. [2] Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
TE-15 NE\xW2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTBwMECwNlg4KM7:TR?= NXPoc5lnW0GQR1XS
LC-2-ad MoTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoS4TWM2OD1yLkCwNFMyPyEQvF2= M{PP[HNCVkeHUh?=
RL95-2 MlzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTBwMECwOlY5KM7:TR?= NXXHd2tYW0GQR1XS
MZ1-PC M{nOWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXwbpNKSzVyPUCuNFAxPzJ7IN88US=> MlPUV2FPT0WU
TE-8 M3q5c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUP6RVE2UUN3ME2wMlAxOTF5IN88US=> MXPTRW5ITVJ?
SW954 NGXFcHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTBwMECxNVkh|ryP NIW1WYZUSU6JRWK=
TE-11 NX7XU3R6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1v2VmlEPTB;MD6wNFEzOyEQvF2= MYDTRW5ITVJ?
PSN1 M{HCdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTBwMECxN{DPxE1? MnHJV2FPT0WU
MOLT-4 NF:5PFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HkVGlEPTB;MD6wNFE1QSEQvF2= NV:zZ5pTW0GQR1XS
697 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHtTWM2OD1yLkCwNVUh|ryP MnrVV2FPT0WU
ETK-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXywcFNpUUN3ME2wMlAxOTV{IN88US=> MoHqV2FPT0WU
TE-10 M2fOeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTBwMECxOVQh|ryP NF7aRphUSU6JRWK=
HUTU-80 NVHOboY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3qwWWlEPTB;MD6wNFE3QCEQvF2= NIC0Oo9USU6JRWK=
NTERA-S-cl-D1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mln3TWM2OD1yLkCwNlA6KM7:TR?= NFnkSYdUSU6JRWK=
MFH-ino M3nOdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7xNJhFUUN3ME2wMlAxOjZ6IN88US=> NV\WfWZVW0GQR1XS
IA-LM MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH70ZWlKSzVyPUCuNFAzQCEQvF2= NUnYNZJQW0GQR1XS
MC116 NXf5NVJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\HTGlEPTB;MD6wNFI5QSEQvF2= NHj5OWpUSU6JRWK=
RKO M{fIRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XRdGlEPTB;MD6wNFI6QCEQvF2= NW\qb4xjW0GQR1XS
MRK-nu-1 NUDBOW1OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHoVZFzUUN3ME2wMlAxOjl7IN88US=> Mn2xV2FPT0WU
VA-ES-BJ NF\hWIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX75UZRLUUN3ME2wMlAxOyEQvF2= NFK5cGhUSU6JRWK=
KALS-1 NYC1WYp{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTPTWM2OD1yLkCwN|A5KM7:TR?= NF\ibXFUSU6JRWK=
BB30-HNC Mkf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTBwMECzNVQh|ryP MWPTRW5ITVJ?
ACN MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PXUmlEPTB;MD6wNFMyPiEQvF2= NYTJU41bW0GQR1XS
TE-9 NWj3SnVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XjVWlEPTB;MD6wNFMzPiEQvF2= M375RnNCVkeHUh?=
SIG-M5 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInNW2RKSzVyPUCuNFA{OjdizszN NYDLN5drW0GQR1XS
no-10 Mn;3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\3NGlEPTB;MD6wNFM3OiEQvF2= NEL5T2JUSU6JRWK=
EW-1 NXfRSFlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jl[2lEPTB;MD6wNFM4OSEQvF2= MYjTRW5ITVJ?
SK-LMS-1 M4Tz[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTuTWM2OD1yLkCwOFAyKM7:TR?= NXHke4t2W0GQR1XS
GT3TKB Mmi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHCS2FKSzVyPUCuNFA1OzRizszN M1zxeXNCVkeHUh?=
ES4 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jPNGlEPTB;MD6wNFQ1QSEQvF2= NIXHOWtUSU6JRWK=
IMR-5 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE[y[HpKSzVyPUCuNFA1PSEQvF2= MUPTRW5ITVJ?
NCI-H1648 NIrn[YxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17VR2lEPTB;MD6wNFQ3QSEQvF2= M3LtZXNCVkeHUh?=
MV-4-11 NXHTUHFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2qzPGlEPTB;MD6wNFQ4PSEQvF2= M1jTSnNCVkeHUh?=
SK-UT-1 NIjsN5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnVflB1UUN3ME2wMlAxPDhizszN M33Zc3NCVkeHUh?=
NB13 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnhcmdbUUN3ME2wMlAxPDlzIN88US=> M{fYRnNCVkeHUh?=
DJM-1 NVf3WHBuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7nV|ZKSzVyPUCuNFA2OyEQvF2= M1uzXXNCVkeHUh?=
ES8 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn2yTWM2OD1yLkCwOVM5KM7:TR?= MonnV2FPT0WU
TE-6 MonvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTBwMEC1O{DPxE1? MkXTV2FPT0WU
KS-1 NVPmTm1rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fxd2lEPTB;MD6wNFU5OiEQvF2= MlizV2FPT0WU
TE-1 MnT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHFSVBKSzVyPUCuNFA3ODZizszN MXvTRW5ITVJ?
ATN-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Hu[GlEPTB;MD6wNFYxQSEQvF2= NIToeXdUSU6JRWK=
A4-Fuk NGPFZZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVW4fpk3UUN3ME2wMlAxPjFzIN88US=> M{j4UnNCVkeHUh?=
ALL-PO NXHiUYVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\KcmlEPTB;MD6wNFY{KM7:TR?= M{T0OHNCVkeHUh?=
BE-13 NHTBeHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fHVmlEPTB;MD6wNFY{PiEQvF2= NF\1W2lUSU6JRWK=
KM12 NXT3OZhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojtTWM2OD1yLkCwOlM4KM7:TR?= NHvXXXNUSU6JRWK=
NOS-1 M165PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPiTWM2OD1yLkCwOlUh|ryP MUXTRW5ITVJ?
SW962 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTBwMEC2OlIh|ryP NF7lOGNUSU6JRWK=
OCUB-M NUW3OllkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHGxO3BKSzVyPUCuNFA3PjJizszN MW\TRW5ITVJ?
NCI-H510A MkniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXpNplyUUN3ME2wMlAxPjZ3IN88US=> NGTvXGFUSU6JRWK=
EW-16 M1zyb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLXWGtYUUN3ME2wMlAxPjl2IN88US=> M4O0fXNCVkeHUh?=
KGN NGPh[nlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDlV2dKSzVyPUCuNFA4OTJizszN MnfEV2FPT0WU
LS-411N MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7JS4dKSzVyPUCuNFA4OTdizszN NXfNSFlZW0GQR1XS
Becker M3K1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnJ[|dwUUN3ME2wMlAxPzJizszN NVi4cGppW0GQR1XS
HC-1 M{SxOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PYO2lEPTB;MD6wNFczOSEQvF2= M1K3bnNCVkeHUh?=
CESS M1ja[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXyyTlBQUUN3ME2wMlAxPzN5IN88US=> NVHxVZVqW0GQR1XS
KURAMOCHI NUjCc2Q1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTBwMEC3OFgh|ryP MXTTRW5ITVJ?
TGBC24TKB M1fJUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPqTWM2OD1yLkCwO|UzKM7:TR?= NWPOclRtW0GQR1XS
SW982 NGLZTWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTBwMEC3OlYh|ryP NIm1S|hUSU6JRWK=
HCE-4 NXrUTI9qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPMTWM2OD1yLkCwO|Y4KM7:TR?= M3q0NnNCVkeHUh?=
LOUCY M1X2bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPW[m83UUN3ME2wMlAxPzd3IN88US=> M1[2dHNCVkeHUh?=
8-MG-BA NXPqdHI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHP6dIhKSzVyPUCuNFA4QTZizszN MoLZV2FPT0WU
HT-144 NVfNZYNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljjTWM2OD1yLkCwPEDPxE1? M3nxenNCVkeHUh?=
LXF-289 NXTzb2h6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLu[WdKSzVyPUCuNFA5OThizszN MXHTRW5ITVJ?
RS4-11 NUfpOYNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTBwMEC4N|Yh|ryP NUj5bGRkW0GQR1XS
DEL NVvRU4JPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfRTWM2OD1yLkCwPFQ2KM7:TR?= MV7TRW5ITVJ?
OCI-AML2 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Ph[GlEPTB;MD6wNFg2OiEQvF2= NWryfYFjW0GQR1XS
CCRF-CEM NHXHWXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\Vb3NKSzVyPUCuNFA5PzFizszN M{D2V3NCVkeHUh?=
A388 NHzhW5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HRWmlEPTB;MD6wNFg4PCEQvF2= NG\lTJJUSU6JRWK=
KNS-42 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTBwMEC4PVEh|ryP MmTzV2FPT0WU
OVCAR-4 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\0R4Y3UUN3ME2wMlAxQTB2IN88US=> MXXTRW5ITVJ?
NCI-H1355 NYGwOYV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLpTWM2OD1yLkCwPVE1KM7:TR?= MlLFV2FPT0WU
BL-70 NGjBT3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LiN2lEPTB;MD6wNFk{KM7:TR?= M4\1d3NCVkeHUh?=
BL-41 M2T1VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTBwMEC5N|Qh|ryP Mm[1V2FPT0WU
A101D Ml7LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzxTlVsUUN3ME2wMlAxQTZizszN M2HMZ3NCVkeHUh?=
HL-60 M1;RNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPSd5lKSzVyPUCuNFA6PjZizszN MmDTV2FPT0WU
COR-L279 M3vodmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTBwMEC5PVkh|ryP MX3TRW5ITVJ?
NCI-SNU-16 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vkRWlEPTB;MD6wNVAxQCEQvF2= NHXPV4hUSU6JRWK=
Calu-6 M1ewNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTBwMEGwNVIh|ryP M4f5cHNCVkeHUh?=
SR NYnMdI5wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPqVllKSzVyPUCuNFExOjZizszN MX\TRW5ITVJ?
QIMR-WIL MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fH[2lEPTB;MD6wNVA{OyEQvF2= MnTLV2FPT0WU
LB647-SCLC M2CyWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTBwMEGwOVEh|ryP NF;GOJBUSU6JRWK=
RPMI-8226 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFKxU4NKSzVyPUCuNFEyODJizszN M1\WdHNCVkeHUh?=
SK-PN-DW MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvLTWM2OD1yLkCxNVEzKM7:TR?= MXzTRW5ITVJ?
SF268 NFu1TnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmi5TWM2OD1yLkCxNVUyKM7:TR?= M4HVS3NCVkeHUh?=
HD-MY-Z MkCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7EXll{UUN3ME2wMlAyOTZ|IN88US=> NW\rSoFEW0GQR1XS
DOHH-2 MmrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXm5TFVyUUN3ME2wMlAyOjB|IN88US=> MYXTRW5ITVJ?
SCC-3 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPpOHFKSzVyPUCuNFEzODRizszN NEHJSHlUSU6JRWK=
ST486 NVzESGI2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILSWWJKSzVyPUCuNFEzODRizszN NWXEdG9{W0GQR1XS
NALM-6 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHQTWM2OD1yLkCxNlE1KM7:TR?= NXnwTodHW0GQR1XS
NCI-H1436 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnJfnVKSzVyPUCuNFEzOzFizszN M363NXNCVkeHUh?=
KE-37 Ml;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXn5XZRKUUN3ME2wMlAyOjN2IN88US=> MkjNV2FPT0WU
RPMI-8402 NF\Gc21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHHSnh5UUN3ME2wMlAyOjV4IN88US=> MUfTRW5ITVJ?
RXF393 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlX2TWM2OD1yLkCxNlU4KM7:TR?= NGTIc|BUSU6JRWK=
KARPAS-45 M3fkb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTPbZRzUUN3ME2wMlAyOjdizszN MXHTRW5ITVJ?
HOP-62 MmCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDnUlRqUUN3ME2wMlAyOjd4IN88US=> MmjMV2FPT0WU
ES1 MoTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\STWM2OD1yLkCxNlg5KM7:TR?= NI[0NVlUSU6JRWK=
L-363 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTBwMEGzOVEh|ryP NIPQWXlUSU6JRWK=
GI-1 M1zx[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTBwMEGzO|Mh|ryP M1jaVHNCVkeHUh?=
CTV-1 MkfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVT2bFFHUUN3ME2wMlAyPDd6IN88US=> MnvBV2FPT0WU
TE-5 MoDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTBwMEG0PVYh|ryP Mn62V2FPT0WU
SNU-C2B NIjrVGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTBwMEG0PVYh|ryP MmrCV2FPT0WU
K-562 M3zze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHnVZFFUUN3ME2wMlAyPTF4IN88US=> MoTrV2FPT0WU
SNB75 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2r3RWlEPTB;MD6wNVU1KM7:TR?= MmfHV2FPT0WU
MOLT-13 NFPhfIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TiZ2lEPTB;MD6wNVY{PyEQvF2= NXHtPVVDW0GQR1XS
LS-123 NVm5PGNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\2OGlEPTB;MD6wNVY3PCEQvF2= NVrnWYVUW0GQR1XS
NCI-SNU-5 NXvkUGpzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI[3dVJKSzVyPUCuNFE4ODFizszN MVfTRW5ITVJ?
Daudi MnvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrVcI5KUUN3ME2wMlAyPzB6IN88US=> NXTiT|dGW0GQR1XS
A253 NUjneFhWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LkcmlEPTB;MD6wNVc{QCEQvF2= MUnTRW5ITVJ?
TGBC1TKB M3vhR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTBwMEG3OVIh|ryP MmrDV2FPT0WU
SJSA-1 NG[5ZpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnkT3lnUUN3ME2wMlAyPzZ5IN88US=> MVnTRW5ITVJ?
NCCIT NYTkUHl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;lSVRKSzVyPUCuNFE4PjlizszN M3\4THNCVkeHUh?=
NCI-H69 NXjlXoZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rjZWlEPTB;MD6wNVc4QCEQvF2= MoTCV2FPT0WU
SH-4 M{TkdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPST45KSzVyPUCuNFE5QTVizszN M1HMbXNCVkeHUh?=
HCC1187 MmW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2j4OWlEPTB;MD6wNVkzPCEQvF2= M{fYVHNCVkeHUh?=
HCC1599 NHnIfVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTBwMEKwNkDPxE1? Mm\lV2FPT0WU
ONS-76 NVPoNZFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{D2cmlEPTB;MD6wNlA{PiEQvF2= MUnTRW5ITVJ?
KU812 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfQXJRKSzVyPUCuNFIxOzlizszN Mo\OV2FPT0WU
ML-2 Ml;VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{myR2lEPTB;MD6wNlA1PyEQvF2= NETScVJUSU6JRWK=
HCE-T M{\Cdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrhVHFpUUN3ME2wMlAzODl{IN88US=> NXriOmt5W0GQR1XS
NCI-H446 NGXLTHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTBwMEKxNVIh|ryP Moe5V2FPT0WU
RPMI-6666 NUTxe25nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;XdWtuUUN3ME2wMlAzOTR7IN88US=> NYnBWZZ5W0GQR1XS
MOLT-16 M1flWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfnTIk1UUN3ME2wMlAzOTV|IN88US=> MUPTRW5ITVJ?
JiyoyeP-2003 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzJR3ZGUUN3ME2wMlAzOTd4IN88US=> NInFR2VUSU6JRWK=
MHH-PREB-1 MoXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHYWJFKSzVyPUCuNFIyQTFizszN MoXXV2FPT0WU
MC-CAR M3\Femdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PMPGlEPTB;MD6wNlMzPiEQvF2= MWTTRW5ITVJ?
BC-3 NWrhZ2c1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2e0RmlEPTB;MD6wNlM1PCEQvF2= NGi1eJpUSU6JRWK=
KINGS-1 NIXKR4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfrTWM2OD1yLkCyN|U2KM7:TR?= Mo[xV2FPT0WU
PF-382 NGPqZZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDDPXNCUUN3ME2wMlAzOzd6IN88US=> NITRWWlUSU6JRWK=
J-RT3-T3-5 MkPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7GTWM2OD1yLkCyN|g{KM7:TR?= MVPTRW5ITVJ?
SF539 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPF[WhKSzVyPUCuNFI1ODFizszN MVzTRW5ITVJ?
LB831-BLC M{PTcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4f1[mlEPTB;MD6wNlQ5PSEQvF2= MoLFV2FPT0WU
DMS-114 MmO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTBwMEK1NFIh|ryP M4PXTXNCVkeHUh?=
LB1047-RCC M4rkN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPCTWM2OD1yLkCyOVEh|ryP M2n2fnNCVkeHUh?=
LB771-HNC MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTrcmtpUUN3ME2wMlAzPTN2IN88US=> NHXYOoFUSU6JRWK=
BB65-RCC NVLCZlRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHuTWM2OD1yLkCyOVM1KM7:TR?= NFzDd4dUSU6JRWK=
BV-173 NF7mWGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7wdoFKSzVyPUCuNFI2PTRizszN NYGxe45DW0GQR1XS
ARH-77 NUL0OZA{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTBwMEK2NFEh|ryP NWGxZ4V6W0GQR1XS
IST-MEL1 NGPHXoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTBwMEK2NlMh|ryP NXHFeWR{W0GQR1XS
NB1 MoKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnYTWJGUUN3ME2wMlAzPjh5IN88US=> MVnTRW5ITVJ?
EoL-1-cell NWjqN|lYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEe2fYVKSzVyPUCuNFI3QDhizszN NGnBTo5USU6JRWK=
KY821 MoD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTBwMEK2PVch|ryP NWnRXmgxW0GQR1XS
CMK NXLaVZN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYCwemp1UUN3ME2wMlAzPzN2IN88US=> NHrSSJFUSU6JRWK=
NCI-H2126 NVjC[Xo3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jNWGlEPTB;MD6wNlc3QCEQvF2= MYHTRW5ITVJ?
NCI-H526 NXrPcHJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLuTWM2OD1yLkCyPFkyKM7:TR?= Mn7sV2FPT0WU
COLO-684 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{CxZmlEPTB;MD6wNlkxQCEQvF2= M3TvS3NCVkeHUh?=
NCI-H747 NE\qdHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjV[5FoUUN3ME2wMlAzQTN|IN88US=> NEPZeGNUSU6JRWK=
JAR M{jnXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTBwMEK5OFYh|ryP M3\TVnNCVkeHUh?=
MEG-01 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTvTWM2OD1yLkCyPVc5KM7:TR?= MX;TRW5ITVJ?
MONO-MAC-6 NGjmbJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn74TWM2OD1yLkCzNFI{KM7:TR?= NEDkfFhUSU6JRWK=
IST-SL1 M2fKNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTBcIJXUUN3ME2wMlA{ODR{IN88US=> MX7TRW5ITVJ?
CPC-N NUOyeXFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLoTWM2OD1yLkCzNFc6KM7:TR?= Mm\YV2FPT0WU
NCI-H1963 NHzqVItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfMcI03UUN3ME2wMlA{OTNzIN88US=> NEW5[FFUSU6JRWK=
K052 M3O0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTBwMEOyOFch|ryP MoCwV2FPT0WU
KM-H2 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnPSIlSUUN3ME2wMlA{OzB5IN88US=> MlW5V2FPT0WU
TE-12 MnfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXzcnpKSzVyPUCuNFM{ODlizszN MUjTRW5ITVJ?
TK10 M2nyR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjUWWdKSzVyPUCuNFM{PTZizszN M{PSSHNCVkeHUh?=
NMC-G1 NVrUNIVFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfiU|NKSzVyPUCuNFM1PTJizszN MnLQV2FPT0WU
no-11 MlK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH35NpNKSzVyPUCuNFM1PzhizszN Mn7tV2FPT0WU
NCI-H524 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjVXVZNUUN3ME2wMlA{PTJ7IN88US=> M3;qWnNCVkeHUh?=
MHH-CALL-2 MkHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;0TWM2OD1yLkCzOVYzKM7:TR?= MlHEV2FPT0WU
GB-1 NIm5bYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vIVWlEPTB;MD6wN|Yh|ryP MWHTRW5ITVJ?
OPM-2 M13xdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV2xO2VqUUN3ME2wMlA{Pjd|IN88US=> Mni0V2FPT0WU
RH-1 NF7TVndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7SO4VzUUN3ME2wMlA{QDF7IN88US=> MXjTRW5ITVJ?
NCI-H64 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnm2TWM2OD1yLkCzPFU4KM7:TR?= NWn5T3NHW0GQR1XS
EVSA-T NUnlUVlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DuUGlEPTB;MD6wN|kzOyEQvF2= MUjTRW5ITVJ?
KARPAS-299 M{fBcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPDSlNKSzVyPUCuNFM6QCEQvF2= NIjpZmZUSU6JRWK=
MZ7-mel MlzTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmf5TWM2OD1yLkC0NFQh|ryP NFj4U25USU6JRWK=
LB373-MEL-D M1nucGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\K[GlEPTB;MD6wOFExPSEQvF2= MYrTRW5ITVJ?
HEL NXT2fI5iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfwbll6UUN3ME2wMlA1OTRizszN MUPTRW5ITVJ?
SW872 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHpW|JKSzVyPUCuNFQzOSEQvF2= MXjTRW5ITVJ?
DU-4475 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTBwMESyOFQh|ryP MVLTRW5ITVJ?
IST-SL2 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTBwMESyO|Uh|ryP MVPTRW5ITVJ?
NCI-H82 NIHM[IdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fQTGlEPTB;MD6wOFMxPyEQvF2= MlPVV2FPT0WU
LC4-1 NGewSpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETDPZpKSzVyPUCuNFQ{PTFizszN NHXxO4tUSU6JRWK=
HDLM-2 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3K2NGlEPTB;MD6wOFM6OiEQvF2= MYrTRW5ITVJ?
MMAC-SF NITOZlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHX4RmNKSzVyPUCuNFQ2OzRizszN MXrTRW5ITVJ?
L-540 NXzESGFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTBwMES2N|kh|ryP M1rpbXNCVkeHUh?=
MZ2-MEL MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3f0WWlEPTB;MD6wOFc1OiEQvF2= NHzwTWlUSU6JRWK=
LU-134-A NVPSPZFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mly1TWM2OD1yLkC0O|c{KM7:TR?= M2DJO3NCVkeHUh?=
UACC-257 NHzLRnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYi1W4tZUUN3ME2wMlA1QDR7IN88US=> M3\uUHNCVkeHUh?=
NCI-H1581 NI\p[YlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvobXpKSzVyPUCuNFQ6PTNizszN NISyc|FUSU6JRWK=
NB17 Ml7uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zt[WlEPTB;MD6wOFk4QSEQvF2= Ml6zV2FPT0WU
SBC-1 NYHlPZFsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTBwMEWwOFIh|ryP NFL4Z|JUSU6JRWK=
TALL-1 MkLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDZTWM2OD1yLkC1NFQ2KM7:TR?= NGKxbppUSU6JRWK=
NCI-H1304 NEDtNnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTqfmJlUUN3ME2wMlA2OjB6IN88US=> NYXLXHVCW0GQR1XS
NEC8 NVT6SXp1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPHW2JKSzVyPUCuNFUzQDZizszN MnWxV2FPT0WU
CAL-148 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXf3OnRvUUN3ME2wMlA2PDN7IN88US=> MkHEV2FPT0WU
CGTH-W-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1e4W2lEPTB;MD6wOVQ1QSEQvF2= NVvKcHF{W0GQR1XS
NCI-H889 MnXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PtemlEPTB;MD6wOVU6OiEQvF2= M2\3OXNCVkeHUh?=
GR-ST NWjZR3hqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LGPGlEPTB;MD6wOVYzOSEQvF2= MkToV2FPT0WU
KARPAS-422 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfOTWtKSzVyPUCuNFU3PSEQvF2= M333TnNCVkeHUh?=
RPMI-8866 NXXGU3o3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTBwMEW3NVIh|ryP NFni[lhUSU6JRWK=
SCLC-21H NEe2WIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTBwMEW4PFQh|ryP MYfTRW5ITVJ?
COR-L88 MnfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rkbGlEPTB;MD6wOVkzPyEQvF2= MYDTRW5ITVJ?
LU-139 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTCTWM2OD1yLkC1PVg3KM7:TR?= NHfBPJNUSU6JRWK=
SF126 MlTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonMTWM2OD1yLkC2NVM{KM7:TR?= NETocWZUSU6JRWK=
NCI-H1882 Mo[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTBwME[0NlQh|ryP NFm0TnpUSU6JRWK=
EW-24 NVPDRZVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLoVFRDUUN3ME2wMlA3PDh|IN88US=> MUTTRW5ITVJ?
CP67-MEL MmrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIGyXXJKSzVyPUCuNFY5OSEQvF2= MYPTRW5ITVJ?
DG-75 M1;Pcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTBwME[4PVkh|ryP NH\Ze3lUSU6JRWK=
LOXIMVI MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTBwMEewNlgh|ryP MlXmV2FPT0WU
HH M1LR[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\kTmlEPTB;MD6wO|E2PyEQvF2= NGOwTmFUSU6JRWK=
K5 M2T0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTBwMEeyNlYh|ryP NWLCbFhUW0GQR1XS
EC-GI-10 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XHPWlEPTB;MD6wO|I2PyEQvF2= NU\EUJg4W0GQR1XS
SK-N-DZ MkLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3y1cGlEPTB;MD6wO|MxPyEQvF2= MYfTRW5ITVJ?
A3-KAW MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\Fb2lEPTB;MD6wO|M2OSEQvF2= MoDpV2FPT0WU
MLMA M{LWXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEf0d|VKSzVyPUCuNFc1PjVizszN NVXrV4pOW0GQR1XS
LB996-RCC M3vpXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfjZodKSzVyPUCuNFc4ODdizszN NGjnTVNUSU6JRWK=
OS-RC-2 M1K3cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\QTY9TUUN3ME2wMlA4PzR6IN88US=> MXHTRW5ITVJ?
CTB-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PxTmlEPTB;MD6wO|gyKM7:TR?= M2fHb3NCVkeHUh?=
IST-MES1 MojFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3sfoZKSzVyPUCuNFc6OTJizszN Mk\aV2FPT0WU
LS-1034 M2LyVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPOTpVpUUN3ME2wMlA5ODN3IN88US=> NHOwT|RUSU6JRWK=
HT M1KzTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\KbFVKSzVyPUCuNFgxQDZizszN MVzTRW5ITVJ?
NCI-H2141 M2rSO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvlRmIyUUN3ME2wMlA5OSEQvF2= MlTLV2FPT0WU
LB2518-MEL NW\yZm9[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVK1N5VsUUN3ME2wMlA5OTRzIN88US=> MXTTRW5ITVJ?
GI-ME-N NEnyNG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTOTWM2OD1yLkC4OFUzKM7:TR?= M4TVZnNCVkeHUh?=
TGW MmnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TWPGlEPTB;MD6wPFYxPyEQvF2= MlvPV2FPT0WU
SK-NEP-1 MkTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1H5WGlEPTB;MD6wPFY1OSEQvF2= NGDDXZhUSU6JRWK=
NOMO-1 NWOwVpRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrHdpozUUN3ME2wMlA6Ojd3IN88US=> M4m2VHNCVkeHUh?=
ES6 Mm\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NECzSlVKSzVyPUCuNFk2QDlizszN Mlu5V2FPT0WU
NCI-H209 MlnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHuTWM2OD1yLkC5O|g3KM7:TR?= MnfOV2FPT0WU
GAK MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfYTWM2OD1yLkGwNVYh|ryP MUTTRW5ITVJ?
BC-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDTU|dKSzVyPUCuNVA{PjFizszN NE\SV2VUSU6JRWK=
KLE NVLqe5VNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2j0e2lEPTB;MD6xNFQ1OyEQvF2= NVq3eoZMW0GQR1XS
EW-3 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTBwMUC5PEDPxE1? M3mwWnNCVkeHUh?=
NKM-1 Mk\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7RVVJKSzVyPUCuNVEyKM7:TR?= MnjNV2FPT0WU
D-336MG MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYniSZhYUUN3ME2wMlEyOjR2IN88US=> MXHTRW5ITVJ?
NB69 Ml\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPW[21KSzVyPUCuNVE{ODFizszN NHziNVlUSU6JRWK=
D-263MG MlnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;ZT3BKSzVyPUCuNVE4OTJizszN NViy[HJuW0GQR1XS
KP-N-YS M2G4dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTBwMUKyPVEh|ryP M{PFWHNCVkeHUh?=
NCI-H1155 NYDBTnh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjOR|JzUUN3ME2wMlEzPTV6IN88US=> Mkn1V2FPT0WU
BOKU MmjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTBwMUK1O|kh|ryP NUDVfXlmW0GQR1XS
LAMA-84 MofoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLYTWM2OD1yLkGyPVkh|ryP MV;TRW5ITVJ?
Raji M4DSNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfaTWM2OD1yLkGzNVE4KM7:TR?= Mn\VV2FPT0WU
LU-65 NIm0T2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLNTWM2OD1yLkGzN|A4KM7:TR?= NViwUFZwW0GQR1XS
NCI-H187 M4K4bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTMW25KSzVyPUCuNVM6OjRizszN NGPjTHhUSU6JRWK=
GCIY MmfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1v0cWlEPTB;MD6xOFkxOSEQvF2= M3vPU3NCVkeHUh?=
NCI-H2107 M3j0Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTBwMUWwPEDPxE1? MkS4V2FPT0WU
NCI-H1522 NXfDbnBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;CXlRKSzVyPUCuNVUzPjZizszN NH:w[2hUSU6JRWK=
NB6 M1i5[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoCyTWM2OD1yLkG1OlI{KM7:TR?= M4D4dXNCVkeHUh?=
EM-2 M1HvWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fh[2lEPTB;MD6xOVcxPiEQvF2= NGroU4RUSU6JRWK=
HCC2218 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2O2cmlEPTB;MD6xOVk5KM7:TR?= NI\n[JRUSU6JRWK=
NCI-H748 MmrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zMZmlEPTB;MD6xOlM4PiEQvF2= NGL5PHBUSU6JRWK=
MS-1 NIHZcmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfXSGVUUUN3ME2wMlE3PTN5IN88US=> NHL3dXpUSU6JRWK=
NB5 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjqTWM2OD1yLkG2OVk4KM7:TR?= NUHMV|hWW0GQR1XS
OMC-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LQW2lEPTB;MD6xOlY5QCEQvF2= MVfTRW5ITVJ?
NCI-H345 MnnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoG4TWM2OD1yLkG2PVI5KM7:TR?= NVHhWW9pW0GQR1XS
L-428 NH3TPWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXhclVKSzVyPUCuNVY6PDVizszN MkDlV2FPT0WU
SCH NW\vendWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTBwMUi2PFUh|ryP MkfhV2FPT0WU
NCI-H1417 MonJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M36yd2lEPTB;MD6xPVIzPyEQvF2= NVjXOGVtW0GQR1XS
COLO-320-HSR NGX0VlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLaTWM2OD1yLkG5OVMzKM7:TR?= MmTFV2FPT0WU
BT-474 M17nOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTBwMkC4PVIh|ryP NVPxcW5XW0GQR1XS
GDM-1 MmPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTBwMkG5O|Eh|ryP NXT2b4V7W0GQR1XS
NCI-H2196 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvCTWM2OD1yLkKyNlM2KM7:TR?= M2fzc3NCVkeHUh?=
KP-N-RT-BM-1 M4TtN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDSZmJKSzVyPUCuNlI{PDlizszN NXHTRpdkW0GQR1XS
KNS-81-FD NF23VpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTBwMkK5OVgh|ryP M{nLU3NCVkeHUh?=
COLO-668 NFXRR2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYX1S3F[UUN3ME2wMlI{Pjd3IN88US=> MoDZV2FPT0WU
C2BBe1 NVziWGJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33BTWlEPTB;MD6yOlc1PyEQvF2= MVfTRW5ITVJ?
Ramos-2G6-4C10 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPBWXVKSzVyPUCuNlY6PTRizszN NYrSZ5BkW0GQR1XS
CAS-1 M4Lnc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHQTWM2OD1yLkK3NFk3KM7:TR?= MlPKV2FPT0WU
GOTO M36yVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2Hhb2lEPTB;MD6yO|g6PCEQvF2= MVfTRW5ITVJ?
LP-1 MnnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHITWM2OD1yLkK4NFU4KM7:TR?= MVzTRW5ITVJ?
NCI-SNU-1 MkLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnETWM2OD1yLkK5OFIzKM7:TR?= M4ro[HNCVkeHUh?=
EB-3 NG\uTllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTBwMkm5O|kh|ryP MnG2V2FPT0WU
MHH-NB-11 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDzXXU5UUN3ME2wMlMxPDB{IN88US=> MVvTRW5ITVJ?
SK-N-FI NGL5SnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3pTWM2OD1yLkOxOlkzKM7:TR?= Mn3tV2FPT0WU
HCC2157 NVrTXmtjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljJTWM2OD1yLkOzPVE{KM7:TR?= NU\4SHVMW0GQR1XS
SIMA MmH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETqXYdKSzVyPUCuN|Q2QDFizszN M4HNcXNCVkeHUh?=
MDA-MB-134-VI MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2ThZmlEPTB;MD6zOlkzQCEQvF2= MlPHV2FPT0WU
NCI-H1694 M{GxTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlz1TWM2OD1yLkO3JO69VQ>? NX3uPJg1W0GQR1XS
EHEB NETOZlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFGwdYZKSzVyPUCuN|kxQDVizszN NIDydHZUSU6JRWK=
U-266 NUHmZVFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HTTGlEPTB;MD6zPVg1PiEQvF2= NEn0OIxUSU6JRWK=
LC-1F NVfjSld6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPRcXFTUUN3ME2wMlQ{PzZ3IN88US=> MmXqV2FPT0WU
SHP-77 M1vKOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml:1TWM2OD1yLkS3PFU2KM7:TR?= MlHYV2FPT0WU
LS-513 M3fWZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTBwNEmzNFch|ryP NX\lR|dEW0GQR1XS

多くの細胞株試験データを見る場合、クリックしてください

体内試験 The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. [4]

お薦めの試験操作(参考用のみ)

細胞試験:

[1]

+ 展開
  • 細胞株: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
  • 濃度: 0.1-100 pM
  • 反応時間: 72 hours
  • 実験の流れ:

    Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.


    (参考用のみ)
動物試験:

[4]

+ 展開
  • 動物モデル: Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
  • 製剤: Dissolved in absolute ethanol with an equal volume of cremophor and diluted 1:4 with sterile physiological saline before use.
  • 投薬量: 20 mg/kg
  • 投与方法: Administered via i.v.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 171 mg/mL (200.25 mM)
Ethanol 18 mg/mL (21.07 mM)
Water Insoluble
体内 順序で溶剤を入れること:
5% DMSO+5% Tween 80+ddH2O
2.5mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 853.91
化学式

C47H51NO14

CAS No. 33069-62-4
保管
別名 NSC 125973

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02181634 Active, not recruiting Cholangiocarcinoma PrECOG, LLC.|Celgene Corporation December 9, 2014 Phase 2
NCT03047265 Active, not recruiting Nasopharyngeal Carcinoma Sun Yat-sen University February 4, 2017 Phase 2
NCT02779855 Not yet recruiting Breast Cancer|Ductal Carcinoma|Invasive Breast Carcinoma|Invasive Ductal Breast Carcinoma H. Lee Moffitt Cancer Center and Research Institute|Amgen April 30, 2017 Phase 1|Phase 2
NCT00001426 Completed Ovarian Neoplasm National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 3, 1995 Phase 2
NCT01419548 Withdrawn Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 29, 2011 Phase 1
NCT01051934 Completed Non-Small Cell Lung Cancer|Adenocarcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) December 29, 2009 Phase 1

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    I am interested in the product S1150 for in vivo studies, could you please give some suggestions for the formulation?

  • 回答:

    S1150 in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 30mg/ml is a suspension. If the you want to inject it, there is another vehicle, 5% DMSO+5% Tween 80+ddH2O. S1150 can dissolve in it at 2.5mg/ml as a clear solution. It is a common formulation we used, but is not cited from reference.

  • 問題2:

    the compound was dissolved into 1ml DMSO and diluted with 1x PBS or water (500ul + 9.5 ml PBS or water). I found the white precipitation goes out. How to figure it out?

  • 回答:

    Paclitaxel has very low solubility in water based solution and that's why it precipitated out once you dilute the stock with water. The vehicle we suggest is: 1% DMSO+30% polyethylene glycol+1% Tween 80.

Microtubule Associated信号経路図

相関Microtubule Associated製品

Tags: Paclitaxelを買う | Paclitaxel ic50 | Paclitaxel供給者 | Paclitaxelを購入する | Paclitaxel費用 | Paclitaxel生産者 | オーダーPaclitaxel | Paclitaxel化学構造 | Paclitaxel分子量 | Paclitaxel代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID